Targeting autoimmunity with CD19-CAR T-cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis
Albach FN, Minopoulou I, Wilhelm A, Biesen R, Kleyer A, Wiebe E, Fleischmann A, Frick M, Damm F, Gogolok J, Serve S, Locher BN, Borie D, Casteleyn V, Siegert E, Dörner T, Alexander T, Furth C, Zernicke J, Movassaghi K, Hütter-Krönke ML, Schrezenmeier E, Schneider U, Bullinger L, Krönke G, Penack O, Simon D (2025)
Publication Type: Journal article
Publication year: 2025
Journal
Book Volume: 64
Pages Range: 4075-4077
Journal Issue: 6
DOI: 10.1093/rheumatology/keaf077
Involved external institutions
Charité - Universitätsmedizin Berlin
Germany (DE)
Kyverna Therapeutics, Inc.
United States (USA) (US)
Deutsches Rheuma-Forschungszentrum (DRFZ)
Germany (DE)
Germany (DE)
Kyverna Therapeutics, Inc.
United States (USA) (US)
Deutsches Rheuma-Forschungszentrum (DRFZ)
Germany (DE)
How to cite
APA:
Albach, F.N., Minopoulou, I., Wilhelm, A., Biesen, R., Kleyer, A., Wiebe, E.,... Simon, D. (2025). Targeting autoimmunity with CD19-CAR T-cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis. Rheumatology, 64(6), 4075-4077. https://doi.org/10.1093/rheumatology/keaf077
MLA:
Albach, Fredrik N., et al. "Targeting autoimmunity with CD19-CAR T-cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis." Rheumatology 64.6 (2025): 4075-4077.
BibTeX: Download